Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Kossoff, Ellen B ^a   Ngamphaiboon, Nuttapong ^a   Laudico, Thomas J ^a   O'Connor, Tracey L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Ixabepilone; Metastatic breast cancer; Weekly

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IXABEPILONE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPOPHOSPHATEMIA; LYMPHEDEMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84655170197     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9726-6     Document Type: Article

References (26)

1. Ixempra Kit (ixabepilone) prescribing information. Princeton: NJ; 2009 (Bristol-Myers Squibb Company).
2. ES Thomas 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 33 5210 5217 (Pubitemid 350232252)
3. ES Thomas 2008 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 26 13 2223
4. DM Bollag 1995 Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 55 11 2325 2333
5. MA Jordan 2002 Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr Med Chem Anticancer Agents 2 1 1 17 (Pubitemid 34649866)
6. M Wartmann KH Altmann 2002 The biology and medicinal chemistry of epothilones Curr Med Chem Anticancer Agents 2 1 123 148 (Pubitemid 34649871)
7. DW Heinz WD Schubert G Hofle 2005 Much anticipated-the bioactive conformation of epothilone and its binding to tubulin Angew Chem Int Ed Engl 44 9 1298 1301 (Pubitemid 40352555)
8. FY Lee 2009 Preclinical efficacy spectrum and pharmacokinetics of ixabepilone Cancer Chemother Pharmacol 63 2 201 212
9. E Rivera J Lee A Davies 2008 Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors Oncologist 13 12 1207 1223
10. GN Hortobagyi 2010 Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes Breast Cancer Res Treat 122 2 409 418
11. JA Sparano 2010 Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 20 3256 3263
12. K Miller 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 2676
13. AD Seidman 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 10 1642 1649
14. Kossoff E. Alternative dosing schedules and administration updates for ixabepilone. J Oncol Pharm Pract. 2010.
15. A Awada 2009 Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy Cancer Chemother Pharmacol 63 3 417 425
16. S Moulder 2010 A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial Breast Cancer Res Treat 119 3 663 671
17. Rugo HS, et al. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab(ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J Clin Oncol. 2010;28(15s):abstract#1040.
18. OA O'Connor 2008 A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma Br J Haematol 143 2 201 209
19. Wilding G, Chen Y, DiPaola RP, Carducci MA, Liu G. E3803: update results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol 2008;26(suppl):abstract#5070.
20. BA Burtness J Manola R Axelrod A Argiris AA Forastiere 2008 A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study Ann Oncol 19 5 977 983 (Pubitemid 351627317)
21. PA Ott 2010 A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma PLoS One 5 1 e8714
22. K De Geest 2010 Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 28 1 149 153
23. EA Perez 2007 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 23 3407 3414 (Pubitemid 47310876)
24. E Thomas 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 23 3399 3406 (Pubitemid 47310875)
25. CTCAE. Common terminology criteria for adverse events. http://ctepcancergov/protocolDevelopment/electronic-applications/ctchtm. 2009;Version 4.0.
26. EA Eisenhauer 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 228 247